Wave Life Sciences has seen its modeled fair value adjusted from US$19.63 to about US$17.68, a cut of roughly 10% in the latest update. This shift aligns with recent Street research that weighs enthusiasm for the RNA editing platform and programs like WVE-006 and WVE-007 against concerns around execution risk, timelines, and a more focused pipeline. As you read on, you will see how these changing assumptions and investor debates shape the evolving narrative around Wave Life Sciences.
Stay updated as the Fair Value for Wave Life Sciences shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Wave Life Sciences.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms, including William Blair, UBS and Ladenburg, have recently started coverage of Wave Life Sciences with positive ratings, pointing to WVE-006 and WVE-007 as key programs.
-
William Blair highlights FDA alignment on a pivotal WVE-006 study planned to begin in 2027 and assigns modeled 2036 sales of US$606m for WVE-006 and US$324m for WVE-007, with probabilities of success already risk adjusted.
-
UBS describes WVE-006 for Alpha-1-antitrypsin deficiency as a high value indication and points to human proof of concept data as a support for Wave Life Sciences' RNA editing platform.
🐻 Bearish Takeaways
-
JPMorgan keeps a Neutral rating and links potential share upside to WVE-007's ability to reach a 5% total body weight loss threshold in obesity, indicating that more convincing data is needed before a more positive stance.
-
Clear Street, Citi and Mizuho have all reduced price targets in recent months, with Clear Street explicitly cutting its modeled probability of success for WVE-007 and removing DMD and HD programs, reflecting concerns about execution and program concentration.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Wave Life Sciences. See which could impact your investment.
How This Changes the Fair Value For Wave Life Sciences
-
Fair value for Wave Life Sciences has moved from US$19.63 to about US$17.68, which is a reduction of roughly 10% in the updated model.
-
Modeled revenue growth has shifted from 39.46% to 21.30%, which lowers the projected future revenue levels used in the valuation.
-
Assumed long run profit margin has moved from 21.93% to 16.91%, which trims expected profitability in the model.
-
Future P/E has changed from about 148.70x to 266.80x, which applies a higher valuation multiple to the updated earnings base.
-
The discount rate has moved from 6.92% to 7.24%, which reflects a modestly higher required return in the model assumptions.
Never Miss an Update: Follow The Narrative
Narratives connect Wave Life Sciences' clinical story, partnerships, and risks to a structured earnings framework and fair value model. They refresh automatically as new data, filings, and research come through, so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Wave Life Sciences to stay up to date on:
-
How upcoming WVE-006 and WVE-007 readouts for AATD and obesity in 2025 and 2026 could act as key potential inflection points for Wave Life Sciences' RNA editing platform.
-
The role of partnerships such as GSK and non-dilutive capital in funding the PRISM RNA platform and new wholly owned programs across rare and prevalent diseases.
-
Key risks around falling collaboration revenue, widening losses, a concentrated pipeline, and a cash runway that currently extends only into 2027.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include WVE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
